AVACTA GROUP PLC (AVCT) — Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the AVACTA GROUP PLC Investor Presentation. Throughout this recorded meeting, investors will be in listen only mode. Questions can be submitted by the Q and A tab situated in the right hand corner of your screen. Just simply type in your question and press send. The company will not be in a position to answer every question received during the meeting itself. Have the company can view your questions submitted today and publish responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Christina Cocklin, CEO. Good morning. Thanks, Paul. Good morning, and thank you everyone for joining us for the data release for Feridoxorubicin in Phase 1b in patients with salivary gland cancers. I'm joined today by two team members, our Chief Medical Officer, Dave Lebowitz, and our translational scientist for this program, Rory Edwards. Let's dive right in. PRECISION is a FAP activated drug delivery program which essentially renders a given toxic drug for oncology silent in the bloodstream and active in the tumor by the binding of the precision peptide to mask the toxic payload in the bloodstream and in the normal tissues. Drug release is then only triggered at the tumor site by FAP, fibroblast activation protein, a protein that's been found in tumor supporting cells. The precision peptide masks the drug, the toxic effects of the drug in normal tissues and in the bloodstream, and that drug is then released actively in the tumor by virtue of fibroblast activation protein or FAP cleaving the peptide and releasing the active drug. Because normal tissues and the bone marrow essentially are not exposed to the toxic effects to the degree that they would be with conventional drugs, this has...